Clinical Trial Update: Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing AC2993 with insulin glargine in patients with Type 2 diabetes who also use a sulfonylurea and metformin; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AC2993 (AC2993)
• Insulin Glargine (insulin glargine)
• Sulfonylurea (sulfonylurea)
• metformin (metformin)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2013-07-31